{"filing":{"accession_number":"0001178253-26-000031","cik":"0001178253","ticker":"SCYX","company_name":"SCYNEXIS INC","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-09","primary_document":"scyx-20260909.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1178253/000117825326000031/scyx-20260909.htm"},"events":[{"id":32546,"run_id":29906,"accession_number":"0001178253-26-000031","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"Sanjay Subramanian was appointed as Chief Financial Officer effective September 9, 2026, succeeding Ivor Macleod who retired from the role. Mr. Subramanian's compensation package includes a $500,000 base salary, $20,000 sign-on bonus, equity grants, and severance provisions, reflecting his extensive capital markets and M\u0026A experience in biotechnology.","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35741,"accession_number":"0001178253-26-000031","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both the departure of CFO Ivor Macleod (effective September 9, 2026) and the appointment of Sanjay Subramanian as the new Chief Financial Officer (effective September 9, 2026). While both events occur, the principal disclosed action centers on the appointment of a new CFO with detailed employment terms, compensation structure ($500,000 base salary, $20,000 sign-on bonus, equity grants, and severance provisions), and extensive background. The appointment is the forward-looking material event, whereas the departure is transitional context. The CFO role is a named executive officer position material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:06:41.191212+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35742,"accession_number":"0001178253-26-000031","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing announces the appointment of Sanjay Subramanian as Chief Financial Officer effective September 9, 2026, along with the concurrent retirement of Ivor Macleod from the same role. While both an appointment and departure occur, the press release centers on welcoming the new CFO and highlighting his qualifications and experience. The appointment of a CFO is material to investors as it affects the company's financial leadership and strategic direction, particularly given Mr. Subramanian's extensive capital markets and M\u0026A experience at other biotechnology companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:06:41.191212+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35741,"accession_number":"0001178253-26-000031","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both the departure of CFO Ivor Macleod (effective September 9, 2026) and the appointment of Sanjay Subramanian as the new Chief Financial Officer (effective September 9, 2026). While both events occur, the principal disclosed action centers on the appointment of a new CFO with detailed employment terms, compensation structure ($500,000 base salary, $20,000 sign-on bonus, equity grants, and severance provisions), and extensive background. The appointment is the forward-looking material event, whereas the departure is transitional context. The CFO role is a named executive officer position material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:06:41.191212+00:00","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-10"},{"id":35742,"accession_number":"0001178253-26-000031","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing announces the appointment of Sanjay Subramanian as Chief Financial Officer effective September 9, 2026, along with the concurrent retirement of Ivor Macleod from the same role. While both an appointment and departure occur, the press release centers on welcoming the new CFO and highlighting his qualifications and experience. The appointment of a CFO is material to investors as it affects the company's financial leadership and strategic direction, particularly given Mr. Subramanian's extensive capital markets and M\u0026A experience at other biotechnology companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:06:41.191212+00:00","company_name":"SCYNEXIS INC","ticker":"SCYX","filing_date":"2026-09-10"}]}